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Abstract
Endometriosis is a complex and multifactorial disease. Chromosomal imbalance screening in endometriotic tissue can be used 
to detect hot-spot regions in the search for a possible genetic marker for endometriosis. The objective of the present study 
was to detect chromosomal imbalances by comparative genomic hybridization (CGH) in ectopic tissue samples from ovarian 
endometriomas and eutopic tissue from the same patients. We evaluated 10 ovarian endometriotic tissues and 10 eutopic 
endometrial tissues by metaphase CGH. CGH was prepared with normal and test DNA enzymatically digested, ligated to adap-
tors and amplified by PCR. A second PCR was performed for DNA labeling. Equal amounts of both normal and test-labeled 
DNA were hybridized in human normal metaphases. The Isis FISH Imaging System V 5.0 software was used for chromosome 
analysis. In both eutopic and ectopic groups, 4/10 samples presented chromosomal alterations, mainly chromosomal gains. 
CGH identified 11q12.3-q13.1, 17p11.1-p12, 17q25.3-qter, and 19p as critical regions. Genomic imbalances in 11q, 17p, 17q, 
and 19p were detected in normal eutopic and/or ectopic endometrium from women with ovarian endometriosis. These regions 
contain genes such as POLR2G, MXRA7 and UBA52 involved in biological processes that may lead to the establishment and 
maintenance of endometriotic implants. This genomic imbalance may affect genes in which dysregulation impacts both eutopic 
and ectopic endometrium. 
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Endometriosis is a common benign gynecological disor-
der affecting about 10% of all women (1). The ectopic tissue 
is histologically identical to the eutopic tissue, differing in 
functional and biochemical aspects (2,3). Endometriosis is 
characterized by dysmenorrhea, dyspaneuria, pelvic pain, 
and infertility or even absence of symptoms (4). Moreover, 
endometriosis suffers malignant transformation at a fre-
quency of 0.7 to 1% (5). 
Its etiology has not been clarified; however, the most 
popular theory proposed to explain it is Sampson’s implan-
tation theory, which postulates that the endometrial cells 
exfoliated during menstruation suffer reflux through the 
uterine tubes, adhere to and proliferate at ectopic sites (6). 
On the other hand, considering retrograde menstruation 
as a nearly universal phenomenon, it is difficult to explain 
why only a fraction of women develops endometriosis (7). 
Some studies suggest a multidimensional etiology including 
hereditary, hormonal and immunological factors (8-10). 
No recurrent chromosomal alteration has been identified 
in endometriotic tissue by karyotyping analysis, probably 
due to the limitations regarding cell culture (5). Compara-
tive genomic hybridization (CGH) allows a genome-wide 
screening of chromosome imbalances without prior knowl-
edge of genomic regions of interest and independent of 
the availability of metaphase cells from the samples to be 
investigated, since genomic DNA is required from the cells 
to be analyzed. Gogusev et al. (11) examined by CGH 18 
endometriotic lesions (6 peritoneal and 2 umbilical nodules, 
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and 10 ovarian endometriomas) and recurrent alterations 
in gene copy number were found in 15/18 cases (83%). 
Genomic losses in chromosomes 1p and 22q were de-
tected in 50% of the cases. Other common losses were 
observed at 5p, 6q, 7p, 9q, 16, and 17q and gains were 
found at 1q, 6q, 7q, and 17q. The authors also evaluated 
by CGH a human endometriosis-derived permanent cell 
line FbEM-1 from both a peritoneal implant and an ovar-
ian endometrioma from a patient with endometriosis and 
observed that gains were more common than losses since 
a significant increase in DNA sequence copy number was 
detected at 1q, 5p, 6p, and 17q (12). 
This methodology was also applied to the evaluation of 
genetic alterations in ovary carcinomas arising within endo-
metriosis (13). Chromosome aberrations were observed in 
the three cases of ovary carcinomas, but no alteration was 
detected in the endometriotic tissue. It was concluded that 
these altered regions might contain tumor suppressor genes 
or oncogenes responsible for the malignant transformation 
of endometriosis. 
Chromosomal imbalance screening in endometriotic 
tissue can be extremely informative in the search for a 
possible genetic marker for the disease. Moreover, the 
literature regarding CGH and endometriosis evaluated 
chromosomal imbalances only in the endometriotic lesions. 
The objective of the present study was to detect chromo-
somal imbalance by CGH in ectopic tissue samples from 
ovarian endometriomas and eutopic tissue from the same 
patients, and, consequently, to evaluate gains and/or losses 
of chromosomal regions, which might be involved in the 
developmental process of the disease. 
Material and Methods
The study was conducted at the Laboratory of Molecular 
Cytogenetics, Department of Genetics, School of Medicine 
of Ribeirão Preto (FMRP-USP), Brazil, in association with 
the Department of Gynecology and Obstetrics (Human 
Reproduction Division) of the same institution. The project 
was approved by the Research Ethics Committee of the Uni-
versity Hospital, FMRP-USP, protocol #11736/2004. Written 
informed consent was obtained from each patient. 
Samples
Twenty samples were collected from 10 patients ac-
cording to the following inclusion criteria: women aged 24 
to 45 years, with regular menstrual cycles and no history 
of any hormonal therapy during the last 6 months before 
collection, and samples obtained during the proliferative 
phase of the menstrual cycle (1st to 12th day). All patients 
were referred to our service by the Endoscopy and Pelvic 
Pain Ambulatory and the Infertility Ambulatory of the Uni-
versity Hospital, FMRP-USP, due to pelvic pain (7 cases) 
or infertility (N = 3; patients 2, 8, 9). None of the patients 
had received treatment for endometriosis. 
The biopsies were collected by laparoscopy during the 
proliferative phase of the menstrual cycle and submitted 
to histopathological analysis. The samples were divided 
into two groups: a) eutopic group (EET) consisting of 
histologically normal endometrial biopsies collected with a 
Novak curette from 10 patients with a diagnosis of ovarian 
endometrioma, and b) ectopic group (OET) consisting of 10 
ovarian endometrioma samples from the same patients. The 
samples were placed in Tissue-Teck® O.C.T. Compound 
cryopreserver (Sakura Finetek USA, Inc., USA) immediately 
after collection, incubated for 15 min in liquid nitrogen, and 
then stored at -80°C.
The endometriosis stage was determined according to 
the classification of the American Society for Reproductive 
Medicine (14). The stages of the cycles were confirmed by 
histological examination and the date of the last menstrua-
tion prior to the procedure.
Comparative genomic hybridization
The protocol for DNA amplification and labeling by 
single cell comparative genomic hybridization was applied 
to all samples (each eutopic or ectopic endometrial DNA) 
and to control DNAs as previously described, with minor 
modifications (15). Briefly, normal female genomic DNA (cat. 
#G1521) was purchased from Promega (Fisher Scientific, 
Ltd., Canada) and used as control. Briefly, MseI restriction 
endonuclease digestion was performed in One-Phor-All-
Buffer-Plus (New England Biolabs, Canada) for 3 h at 37°C. 
Primers were annealed by adding the Lib1-primer (5’-AGT 
GGG ATT CCT GCT GTC AGT-3’) and ddMse-primer (5’-
TAA CTG ACA GCdd-3’). Annealing was started at 65°C 
(also serving to inactivate the restriction enzyme before 
ligation) and the temperature was reduced to 15°C with 
a ramp of 1°C/min. At 15°C, 1 µL ATP (10 mM) and 1 µL 
T4-DNA-Ligase (5 units; Boehringer Mannheim, Germany) 
were added, and primers and DNA fragments were ligated 
overnight. For primary amplification, 40 µL consisting of ex-
pand long template and buffer 1 (Boehringer Mannheim) and 
dNTPs (10 mM) were added to the 10-µL ligation reaction 
volume. The PTC-200 thermal cycler (MJ Research) was 
programmed for a) 68°C for 3 min, b) 15 cycles of 94°C for 
40 s, 57°C for 30 s and 68°C for 1 min and 30 s (with an 
additional second for each cycle), c) 8 cycles of 94°C for 40 
s, 57°C for 30 s (with an additional second for each cycle) 
and 68°C for 1 min and 45 s (with an additional second for 
each cycle), d) 22 cycles of 94°C for 40 s, 65°C for 30 s 
and 68°C for 1 min and 53 s (with an additional second for 
each cycle), and e) 1 cycle of 68°C for 3 min and 40 s. A 
second amplification was performed and DNAs were then 
individually and differentially labeled using 2 µL of the pri-
mary PCR and 60 mM Tris-SO4, pH 9.1, 10 mM (NH4)SO4, 
1.5 mM MgSO4, 2 U of Elongase, 1.4 μM oligonucleotide 
LIB1, 330 μM dGTP, dATP, and dCTP, 290 μM dTTP, and 
40 μM digoxigenin 11-dUTP (for the control DNA) or biotin 
16-dUTP (for the ectopic and eutopic DNA). Amplification 
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conditions were: 1 cycle of 94°C for 1 min, 60°C for 30 s, 
68°C for 2 min; 10 cycles of 94°C for 30 s, 60°C for 30 s 
and 68°C for 2 min with 20 additional seconds for cycle. 
Before using the labeled DNA (2 μg), primers were removed 
by TruI (Fermentas, Canada) digestion.
Equal amounts (8 µg) of each labeled endometriotic 
DNA and a normal female genomic DNA control were co-
precipitated with Human Cot-1 DNA (1 mg/mL). Each labeled 
probe DNA was resuspended in 12 µL hybridization mixture 
consisting of 100% formamide and 30% dextran sulfate/4X 
SSC. After denaturation at 75°C for 5 min, each labeled 
DNA probe was co-hybridized to normal human metaphase 
spreads prepared by a phytohemagglutinin-stimulated pe-
ripheral blood lymphocyte culture previously denatured at 
70°C for 2 min. Hybridization was carried out at 37°C for 
72 h. The slides were washed three times at 45°C for 5 min 
each in 50% formamide/2X SSC, followed by three washes 
at 45°C in 0.1% SDS/0.1X SSC and three washes at 45°C 
in 2X SSC. Biotinylated DNA sequences were visualized 
with fluorescein isothyocyanate (FITC)-conjugated avidin 
and digoxigenin-labeled sequences were detected using 
anti-digoxigenin-rhodamine. Chromosome preparations 
were counterstained with 4’-6-diamidino-2-phenylindole 
dihydrochloride (DAPI; Sigma-Aldrich Co., USA).
Digital image analysis
The metaphases were examined using an epifluores-
cence microscope Axioskop 2 Plus (Zeiss, Germany), with 
images captured and analyzed by Isis FISH Imaging System 
V 5.0 (Metasystem Gmbh, Germany). For each sample, 25 
non-overlapping images were captured, and the data from 
10 representations of each chromosome were combined. 
Gains and losses of chromosomes or chromosomal regions 
were detected on the basis of the ratio profiles deviating from 
the green to red balance value of 1.0 within 0.8-1.2 limits. 
The threshold values were determined according to previ-
ous reports (11,13). The centromeric and heterochromatic 
regions and the short arm of acrocentric chromosomes 
were not included in the interpretation of gains and losses. 
Chromosome Y was excluded from the analysis because 
the reference and test DNAs were from females. 
Results
Twenty endometrial tissue samples consisting of ten 
eutopic endometrial tissue samples and ten ovarian endo-
metriomas were analyzed by CGH. We detected chromo-
somal alterations in both groups, which are summarized 
in Table 1. Alterations were detected in 4/10 samples from 
the ectopic group and also in 4/10 samples from the eu-
topic group. The endometriomas presented losses at 9p 
(one case) and gains at 1p (1 case), 11q (1 case), 16q (1 
case), 17p (2 cases), 18p (1 case), 19p (3 cases), 19q (2 
cases), 20q (1 case), 22q (1 case), and Xq (1 case). The 
alterations observed in the eutopic group were gains at 
1p (2 cases), 11q (2 cases), 16q (1 case), 17p (1 case), 
17q (2 cases), 19p (4 cases), 19q (3 cases), 20q (1 case), 
and 22q (3 cases). Figure 1 illustrates all the alterations 
found in the ectopic and eutopic groups. Chromosomal 
regions 1p33-pter, 11q12-q13.1, 17p11.1-p12, 17q25-qter, 
19, 20q11.23-qter, and 22q11.2-qter presented significant 
alterations.
Comparative analysis showed 5 patients (1, 2, 5, 6, 
and 8) without alterations in either tissue (OET/EET). 
One patient presented alteration only in the ectopic tissue 
(OET9), as a gain at 17p. One patient presented alteration 
only in the eutopic tissue (EET3), as gains at 19p and 22q. 
Chromosomal alterations were observed in both tissues in 
3 patients (OET4/EET4, OET7/EET7, and OET10/EET10). 
All the alterations observed in the eutopic tissue (gain at 
16q, 19p, and 19q) from patient 4 were also found in the 
ectopic tissue, in which gain at Xq was also observed. 
Table 1. Chromosomal aberrations detected by comparative genomic hybridization in ectopic and eutopic tissues from 10 endometrio-
sis patients.
Ectopic        Eutopic
OET1 ND EET1 ND
OET2 ND EET2 ND
OET3 ND EET3 +19p, +22q
OET4 +16q, +19p, +19q, +Xq EET4 +16q, +19p, +19q
OET5 ND EET5 ND
OET6 ND EET6 ND
OET7 +1p, -9p, +11q, +17p, +18p, +19p, +19q, +20q, +22q EET7 +1p, +11q, +17q, +19p, +19q, +22q
OET8 ND EET8 ND
OET9 +17p EET9 ND
OET10 +19p   EET10 +1p, +11q, +17p, +17q, +19p, +19q, +20q, +22q
- = loss; + = gain; ND = not detected; OET = ovarian endometrioma tissue; EET = eutopic endometrium tissue from the same patient.
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Figure 1. Chromosomal aberrations detected by comparative genomic hybridization in our samples. A, Losses and gains in 10 ectopic 
ovarian endometrioma samples. B, Losses and gains in 10 eutopic tissue samples from endometriosis patients. The numbers 1 to 10 
at the top of each panel refer to patient identification. Losses in red and gains in green.
Comparative genomic hybridization and endometriosis 803
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Patient 7 presented gains at 1p, 11q, 19p, 19q, and 22q 
in both tissues, but gains were observed at 17q only in 
the eutopic tissue and gains at 17p, 18p and 20q, as well 
as losses at 9p, were reported only in the ectopic tissue. 
Patient 10 presented gain at 19p in both tissues; however, 
gains at 1p, 11q, 17p, 17q, 19q, 20q, and 22q were found 
only in the eutopic tissue. The increased number of chro-
mosomal alterations in patients 4, 7, and 10 did not show 
any correlation with symptom severity or a poor prognosis. 
None of the patients presented ovarian tumors within a 
3-year follow-up.
The 11q, 17p, and 17q regions were selected as critical 
regions because they involve non-centromeric regions (or 
any other repetitive sequence region) and were detected in 
more than one sample. Some aberrations were previously 
described in normal tissues at 1p, 19, and 22, G-C-rich 
regions known to produce false-positive results by CGH 
(13). Nevertheless, we also considered 19p as a critical 
region because, differently from regions 1p and 22, it was 
maintained in the 3 cases of evolution (samples 4, 7, and 
10) both in the eutopic and ectopic tissue, indicating a 
clonal origin.
Discussion
A different theory for each of the three types of en-
dometriosis has been proposed (16-18), and it has been 
discussed that endometriosis has a genetic component 
and that acquired chromosome-specific aberrations could 
be involved in its pathogenesis. There are no reports re-
garding genomic alterations detected by metaphase CGH 
when comparing ovarian endometriomas and eutopic 
endometrium. We evaluated 10 ovarian endometrioma 
samples (ectopic tissue) and 10 eutopic samples from the 
same patients by CGH. The selection of paired samples 
is mandatory to minimize the individual genomic variability 
in the women analyzed. Considering the diversity of the 
Brazilian population, our control was the patient herself 
(eutopic tissue) in order to exclude individual genetic varia-
tion (polymorphisms and copy number variations) with no 
phenotypic correlation. 
Alterations involving mainly gains of chromosomal 
regions were observed in both tissues. Some regions 
were excluded from CGH analysis, such as centromeric 
regions and heterochromatic repeat regions such as the 
p-arms of the acrocentric chromosomes, which cannot be 
evaluated because they are blocked by the unlabeled Cot-1 
DNA in the hybridization. Telomeric regions were excluded 
because the absolute green and red fluorescence intensi-
ties gradually decrease at telomeres. Also, because some 
alterations were previously detected in normal tissues at 1p, 
16p, 19, and 22, these G-C-rich regions known to produce 
false-positive results by CGH were excluded from analysis 
(13,19-22) except for region 19p that was identified in the 
present study as the only imbalance of clonal origin, which 
is maintained in the three cases of evolution. We detected 
alterations in 4/10 ovarian endometrioma samples (40%) 
and, differently from other reports (11,12), we observed 
gains mainly at 1p, 11q, 16q, 17p, 18p, 19p, 19q, 20q, 22q, 
and Xq, and losses at 9p. The literature is unclear about 
the genetics of endometriosis and there are few studies 
using CGH. There are reports of both total absence of 
aberrations detected by CGH in all endometriosis samples 
(13,23) and of gains and losses at chromosomal regions 
in 15/18 endometriotic samples (83%), mainly losses at 
1p32-36, 5p, 6q, 7p14-p22ter, and 22q12.3-qter and gains 
at 6q, and 17q (11). 
This discrepancy can be explained by the heterogene-
ity of the sample origin. Mhawech et al. (13) evaluated 
endometriotic tissue from patients with ovarian carcinomas 
arising within endometriosis and no chromosomal alteration 
was found in the endometriotic tissue. They suggested that 
there are no established correlations between genomic 
alterations and a poor prognosis, although their study was 
performed on only 3 patients. We also did not observe any 
correlation between the presence or absence of chromo-
somal alterations and clinical follow-up in terms of fertility and 
cancer. In another study, an abnormal genomic profile was 
observed in 10/10 samples of ovarian carcinoma. Chromo-
somal alterations such as losses of 6q, 9p, 10q, 21q, 22q, 
and gains of 8q, 9q, and 12p were found in ovarian cancer 
samples analyzed by BAC-array-CGH (24). Array-CGH data 
for 5 endometriosis samples showed alterations in different 
chromosomes but mainly at 1p, 3p, and 4p (25). Besides, 
there was a considerable diversity in the alterations among 
patients, since they did not share any common alteration, 
probably due to the heterogeneity of the samples. Using 
array-CGH, Wu et al. (26) observed genomic alterations 
both in ectopic and eutopic tissues from peritoneal and 
ovarian endometriosis. 
In the eutopic group, 40% (4/10) presented chromo-
somal alterations involving gains at 1p, 11q, 17p, 17q, 19p, 
19q, 20q, and 22q. These results suggest that the histologi-
cally normal endometrium from women with endometriosis 
can present genomic alterations, as reported previously 
(17). Moreover, in the majority of our samples, the altera-
tions observed in the eutopic tissue were different from 
those observed in ectopic tissue. In one case (patient 4), 
all alterations found in eutopic tissue were also observed 
in endometriotic tissue, which also presented gain at Xq. 
In three cases (3, 7 and 10), both tissues shared some 
alterations. This apparent lack of homogeneity indicates 
multiple paths leading to endometriosis. The observation 
of different alterations in both tissues from the same patient 
challenges the applicability of Sampson’s theory. Accord-
ing to retrograde reflux theory, it is assumed that the same 
alterations found in the eutopic endometrium are also 
found in the endometriotic tissue and that the latter should 
present additional alterations responsible for adhesion, cell 
proliferation and angiogenesis, which would differentiate it 
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from the eutopic tissue. 
We observed that alterations at 11q12.3-q13.1, 17p11.1-
p12, 17q25-qter, and 19p were the most frequent in our 
cohort and at least one of them (19p) appeared in four 
samples related to three patients. Some of these genomic 
alterations are critical because they contain genes related 
to angiogenesis, cell cycle regulation, immune response, 
and cell adhesion (27), which may play a role in the de-
velopment, establishment and maintenance of ovarian 
endometriomas. 
In a previous study, using the same ovarian endometri-
oma samples, we analyzed the differential gene expression 
profiles of eutopic and ectopic tissues from women with 
endometriosis. Genes POLR2G [polymerase (RNA) II 
(DNA directed) polypeptide G], MXRA7 [matrix-remodeling 
associated 7] and UBA52 [ubiquitin A-52 residue ribosomal 
protein fusion product 1] were overexpressed in the en-
dometriotic lesions and were located in our chromosome 
gain regions 11q13.1, 17q25.1, and 19p13.1-p12 detected 
by CGH, respectively (28). These genes were categorized 
by their functions in biologic processes according to the 
Gene Ontology (GO) terms (http://www.geneontology.
org): POLR2G plays a role in signal transduction; UBA52 
is responsible for cell migration, cell motility, cell-cell signal-
ing, positive regulation of transcriptions, growth regulation, 
cell communication, and cell death, and MXRA7 acts on 
tissue remodeling.
The literature continues to be unclear concerning the 
regions of genomic imbalances in endometriomas. It is 
suggested that genomic variability or results from different 
stages of the proliferative process may play a role. Our 
goal was to perform a screening investigation for identify-
ing chromosomal imbalances that might be involved in 
endometrioma outcome and/or its development. Despite the 
time-consuming procedures related to CGH analysis, the 
methodology is still a suitable and efficient tool for further 
studies in an attempt to define candidate genes. 
Genomic imbalances in 11q12.3-q13.1, 17p11.1-p12, 
17q25.3-qter, and 19p were detected in eutopic and/or ec-
topic endometrium from women with ovarian endometriosis. 
These regions contain genes involved in biological pro-
cesses that may lead to the establishment and maintenance 
of endometriotic implants. This genomic imbalance may 
affect genes in which dysregulation impacts both eutopic 
and ectopic endometrium.
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